Are probiotics or prebiotics useful in pediatric irritable bowel syndrome or inflammatory bowel disease?

Stefano Guandalini *

Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, The University of Chicago, Chicago, IL, USA

MINI REVIEW ARTICLE
Published: 28 August 2014
doi: 10.3389/fmed.2014.00023

INTRODUCTION

Irritable bowel syndrome (IBS) is a very common disorder, affecting up to 20% of children and teenagers (1), equally involving boys and girls (2) and causing an important health and social burden and with substantial costs (3, 4). IBS is a functional gastrointestinal disorder (FGID) characterized by the association of recurrent abdominal pain to a change in stool consistency or frequency toward a diarrhea- or a constipation-predominant pattern. Its treatment remains largely unsatisfactory.

Inflammatory bowel diseases (IBDs) are a group of chronic, incurable inflammatory disorders of the gastrointestinal tract [mostly represented by Crohn’s disease (CD) and ulcerative colitis]. Their cause is unknown, but genetic, immunologic, and environmental factors are involved. The peak age of onset for CD is 15–30 years, but it may occur at any age. About 10% of cases have their onset before the age of 18, with CD being more frequent in girls, while ulcerative colitis is more common in boys (5). The disease is one of the most prevalent gastrointestinal disease burdens in Western societies and it has become more widespread; its rise in incidence has been reported in all age groups including early childhood (6).

Prebiotics (7) are carbohydrates that transit undigested through the small intestine and eventually reach the colon where they stimulate the growth and/or the activity of beneficial bacteria, mostly bifidobacteria and lactic acid bacteria. Prebiotics include galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS), inulin, and β-glucan (8). The potential for their use in IBS and IBD, in addition to their stimulatory effect on potential probiotic microorganisms, stems also from the observation that some prebiotics (e.g., mannanoligosaccharides, inulin, or β-glucan), are thought to be “immunosaccharides,” i.e., they might act as direct stimulators of innate immunity (9).

Probiotics on the other hand are defined as “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host” (10).

There is a conceivable benefit in their use in both, IBS and IBD. In IBS, alterations in the gut microbiota composition have been well described (reviewed in a recent report by the Rome working team) (11) and recent evidence has elucidated the growing importance of the microbiota–gut–brain axis in the development of IBS (12). As for IBD, the potential role for such compounds appears logical: the endogenous intestinal microbiota plays a central role in

Keywords: irritable bowel syndrome, functional gastrointestinal disorders, inflammatory bowel disease, probiotics, VSL#3, Lactobacillus, Crohn’s disease, ulcerative colitis
the disease development, and various probiotics have been found effective in a variety of animal models.

This review will examine the current status of the utilization of probiotics and prebiotics in children for both disorders.

**PROBIOTICS IN IBS**

Irritable bowel syndrome is defined (13) by the association of abdominal pain with a change in stool pattern in the absence of an organic cause. It is a very prevalent FGID, affecting up to 50% of the children and teenagers seen by a gastroenterology practice (14, 15) and causing significant health care costs and a negative impact on quality of life (16).

Changes in gastrointestinal motility, brain/gut interaction, low-grade inflammation, psychosocial disturbance, visceral hypersensitivity, and altered microbiota appear to contribute to various extents to its onset (17, 18). It is also possible that IBS results from different pathogenetic factors that contribute in various degrees in different patients (19).

How could probiotics be useful in IBS? IBS appears often to follow an episode of gastroenteritis (“post-infectious IBS”), (20) and intestinal microbiota changes have been described in patients with IBS (21–23); furthermore, it is quite conceivable that microbiota may interfere with additional factors involved in the pathophysiology of IBS (24, 25).

In adults, several trials have been published, mostly of a small scale and bearing in general promising results (17, 26, 27).

In children, however, fewer randomized clinical trials (RCTs) are available.

**EFFECTS OF PROBIOTICS ON ABDOMINAL PAIN**

We conducted a double-blinded, placebo-controlled, cross-over RCT (28) examining the effect of the probiotic mixture VSL#3, a proprietary preparation consisting of a high concentration of eight different probiotic strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, and Streptococcus thermophilus), in children and teenagers with IBS. Our results showed that while the patients were taking VSL#3, they experienced a significant (p < 0.05) improvement in the global subjective relief of symptoms score as well as in the score for abdominal pain/discomfort. Similarly, significant benefits were found for bloating/gassiness and for caregivers’ satisfaction with their child improvement, while no significant improvement was seen for diarrhea or constipation.

In 2014, systematic review and meta-analysis (29) on the effect of different probiotics as a treatment for FGID in children and teenagers included nine trials, five of whom, including our trial (28), focused on abdominal pain-related FGID (15, 28, 30–32), and four on bowel changes-related FGID (33–36).

The meta-analysis concluded that the use of Lactobacillus GG, Lactobacillus reuteri DSM 17938 and VSL#3 significantly increased treatment success in children with abdominal pain-related FGID, particularly those with associated bowel changes. Of interest, L. reuteri DSM 17938’s significant decrease of abdominal pain intensity persisted after the removal of the probiotic, indicating a lasting effect of the supplementation (31).

**EFFECTS OF PROBIOTICS ON FUNCTIONAL DIARRHEA OR CONSTIPATION**

Notably, the two RCTs that assessed the effect of probiotics (Lactobacillus GG and VSL#3) on the parameter of diarrhea (15, 28) did not show any benefit of the intervention.

Four studies included in the meta-analysis assessed constipation-related FGID. The probiotics used were Lactobacillus GG associated with lactulose, L. casei rhamnosus Lcr35, B. longum, and Bifidobacterium lactis DN-173 010 (33–36). The results were disappointing, with no evidence that probiotics are more effective than placebo in overall outcome of treatment or in increasing defecation frequency in constipated children and with inconsistent data on the improvement in stool consistency (34, 35).

**PROBIOTICS IN IBD**

It is now well established that intestinal microbiota play an important role in IBD (37). Probiotics appear therefore as a logical option to positively influence the clinical course of IBD. They possess anti-inflammatory action and enhance the gut barrier, and since the inflammation in IBD results from an altered mucosal immune response to luminal bacterial antigens, the use of live microorganisms may conceivably favorably affect the overall microbial balance.

The mechanisms of action underlying the benefits of probiotics in IBD have been largely and quite extensively investigated in a variety of in vitro and in vivo animal experiments [reviewed in Ref. (38)]. It is thought that in general, the effects manifested by a specific probiotic depend on its metabolic properties, the molecules surface-expressed molecules, and the products they secrete (39).

However, in spite of the strength of the conceptual basis for the beneficial use of probiotics, and of the extensive experimental data in animal models, the existing literature – and in particularly RCTs – on the use of probiotics in IBD is relatively limited. I will consider here only published studies reporting RCTs with a comparator, either placebo or an accepted standard therapy.

**CROHN’S DISEASE**

A meta-analysis on probiotics in adult IBD published in 2012 (40) included eight papers in CD: four conducted in active CD (only one of which placebo-controlled). The latter trial reported a lower relapse rate after 12 months receiving of Escherichia coli Nissle 1917 added to prednisolone therapy (41). The other four studies were conducted in patients with CD in remission: two used Lactobacillus GG (42, 43) and two Lactobacillus johnsonii (44, 45). In none of the studies were probiotics more effective than placebo in preventing relapses.

A subsequent and recent meta-analysis (46) included 23 RCT (12 in UC, 4 in “pouchitis,” and 7 in CD, only 3 of them in children) with a total of 1763 participants: again results were quite disappointing, as in none of the trials in CD probiotics appeared to be of any significant benefit. Focusing on the three pediatric trials (41, 43, 47) where the remission/response rates in acute CD were reported, in none was any positive effect of probiotics supplementation shown (p = 0.35, RR = 0.89).
Seven RCTs (including only one in children, reported in more detail below) examined the frequency of and timing to clinical relapses in CD patients who were in remission. Again, no difference was found between the probiotics-supplemented patients and the control ones ($p = 0.71, RR = 1.09$).

In children, a randomized, placebo-controlled trial of the probiotic *Lactobacillus GG* (48) with the aim of comparing the remission in patients that receive *Lactobacillus* GG added to standard therapy was unable to demonstrate that this probiotic would prolong remission time in patients with CD already in remission on standard therapy. In fact, the time to relapse and proportion of patients relapsing was essentially identical in both *Lactobacillus* GG and placebo groups.

### Ulcerative Colitis

Twelve of the 23 RCTs included in the 2014 meta-analysis (46) were conducted in UC patients.

Nine studies analyzed the remission/response in acute UC, utilizing bifidobacteria, *E. coli* Nissle 1917, and VSL#3, while the overall analysis of these RCTs showed significant benefit from the use of probiotics, the sub-analysis based on probiotic utilized documented such significant effect only for VSL#3 (49–53).

*Escherichia coli* Nissle 1917 is one of the few probiotics licensed as a medicine in Europe where it is utilized in patients with ulcerative colitis; its genome has recently been characterized (54). In spite of a promising open-label pilot trial in 34 children in 2008 (55), no further trial have been conducted in children. In adults, the meta-analysis’ subgroup analysis (46) failed to document evidence of efficacy, and a recent trial in 100 patients (56) not included in the meta-analysis, also failed to show any benefit in addition to conventional therapy. In addition, treatment with this probiotic without a previous antibiotic treatment appeared to be actually detrimental, with fewer patients reaching clinical remission (56).

Are probiotics efficacious in maintaining the remission achieved pharmacologically? Five trials in UC addressed this issue, showing no advantage of probiotics administration when compared to placebo only (RR 0.89, 95% CI 0.66–1.21). It is, however, remarkable that the only pediatric trial also employing VSL#3 (49) showed actually efficacy of the probiotic (RR 0.29, 95% CI 0.10–0.83). This trial included 29 children, with a recent diagnosis of mild to moderate UC who received initially prednisone and mesalazine plus either placebo or VSL#3 for induction, and once remission had been obtained, they remained on mesalazine plus either placebo or VSL#3. The patients were evaluated at 1 month, 2 months, 6 months, and 1 year after diagnosis or at the time of relapse. An endoscopy was additionally performed at the time of diagnosis and then repeated at 6 months, 12 months, or at the time of relapse. The study found that not only the remission but also the relapse rates were better in the patients treated with VSL#3; furthermore, endoscopic and histological scores were significantly better in the VSL#3 group than in the placebo group ($p < 0.05$).

Another pediatric trial, not included in the 2014 meta-analysis, examined 31 children with mild to moderate ulcerative proctitis/proctosigmoiditis (57); they received by enema a solution with *L. reuteri* ATCC 55730 or placebo during 8 weeks, in addition to the oral treatment with mesalazine. A clinical, endoscopic, histological, and immune evaluation (IL-10, IL-1b, TNFα, and IL-8) was performed. Clinical and endoscopic improvements were shown to be better in the probiotic group, and the histological score was significantly decreased in the *L. reuteri* group ($p < 0.01$). In the *L. reuteri* group, a significant increase in the mucosal expression levels of IL-10 and a significant decrease in the levels of IL-1b, TNFα, and IL-8 mucosal expression levels ($p < 0.01$) were also documented.

### Conclusions on the Efficacy of Probiotics in Pediatric IBS and IBD

In IBS, some strains of probiotics offer a modest but meaningful benefit in the treatment of FGID in children, and especially in the treatment of abdominal pain. Considering their outstanding safety profile and the scarcity of alternative safe treatment options, they appear to have an interesting role.

As for IBD, at present there is no evidence of efficacy for any strain in CD. It must, however, be considered that CD is a very heterogeneous condition, with varying degrees of genetic components, very different phenotypes, and variable degrees of severity. It is therefore very likely that the patient-probiotic profiles so far examined are not exhaustive; a better refinement of the strains, their dosage, and their specific applications to well-identified subgroups of patients may yield valuable information and possibly some useful therapeutic implications. In ulcerative colitis on the other hand, there is already evidence of efficacy for the probiotic mixture VSL#3. Further, larger prospective RCTs appear definitely warranted.

### Prebiotics in IBS

Four RCTs have investigated the efficacy of prebiotics to treat IBS symptoms, all of them in adult patients. The first RCT was a crossover trial where 21 patients with IBS were given 6 g/day of FOS (58). There were no significant deviations in symptoms for the treated or control group. The second study conducted by Olsen and Gudmand-Hoyer involved 96 patients with IBS who were given either 20 g/day of FOS or placebo for 12 weeks (59). This high dose increased symptoms at 4–6 weeks thereby suggesting high dosage of prebiotics such as FOS would be ineffective and potentially even dangerous for treatment of IBS. The third study involved 105 patients with functional bowel disorders who were administered 5 g/day of oligofructose (60). Although improvements in global symptoms and bloating were noted, only 50 patients could be included in the final analysis due to withdrawal or violation of protocol. The latest study was conducted over a period of 4 weeks and involved random administration of 3.5 g/day of GOS, 7 g/day of GOS, or placebo to 44 IBS patients (61). The administration of GOS at both doses resulted in an increased predominance of bifidobacteria in fecal samples; and the lowest dose also resulted in significant improvement in bloating, flatulence, and global relief of IBS symptoms. However, higher dosage of GOS caused worse bloating symptoms.

Thus, with all the risks involved in drawing conclusions from only four studies and keeping in mind no data are available so far in children, it is quite conceivable a low to moderate dose of prebiotics might provide some symptom relief, while higher doses may end up being detrimental. This negative effect may well be related to increased luminal gas production following fermentation. In
PREBIOTICS IN IBD
In spite of a substantial amount of promising data obtained in animal systems (65–68) there are few studies investigating the efficacy of prebiotics in humans with IBD, and none in children. An open-label study with FOS supplementation in 10 adult CD patients (69) showed that FOS improved disease activity index, increased fecal bifidobacteria concentrations and modified mucosal dendritic cell function. More recent RCT in 105 patients with CD randomized to receive FOS (n = 54) or placebo (n = 49) failed to show any significant difference in the number of patients achieving a clinical response between the FOS and placebo groups (70).

In an open trial involving patients with mild to moderate UC who had been unresponsive or intolerant to standard treatment, patients received 20–30 mg of germinated barley food (GBF) in a daily feeding (71). At 4 weeks, the GBF treatment had resulted in clinical and endoscopic improvement regardless of initial extent of disease, and the improvement was linked to elevated butyrate concentration in stool. A study by Kanauchi et al. (72) found that GBF increased levels of Bifidobacterium and Eubacterium limosum and appeared to prolong remission in UC patients. Casellas et al. in a placebo-controlled RCT on 19 UC patients treated with mesalazine showed that the group who received oligofructose-enriched inulin supplementation had a lower fecal calprotectin than controls (73).

CONCLUSIONS ON THE EFFICACY OF PREBIOTICS IN PEDIATRIC IBS AND IBD
Prebiotics in IBS have not been studied in children; hence no conclusion can obviously be drawn. The tricky dose–effect relationship found in adult makes their use in children not promising and probably potentially quite limited.

In IBD, again no data are available in pediatric age. Here, however, considering some positive effect in the limited studies available in adults, it would appear that prebiotics may have some potential. Needless to say, much more evidence needs to be generated before any meaningful clinical indication can be identified.

REFERENCES
1. Di Lorenzo OC, Rasquin A, Forbes D. Childhood functional gastrointestinal disorders: child/adolescent. 3rd ed. In: Drossman DA, editor. Rome III: The Functional Gastrointestinal Disorders. Lawrence: Allen Press, Inc (2006). 739 p.
2. Hyams JS, Burke G, Davis PM, Rzepecki B, Andulonis PA. Abdominal pain and irritable bowel syndrome in adolescents: a community-based study. J Pediatr (1996) 129(2):220–6. doi:10.1016/S0022-3476(96)70246-9
3. Koloski NA, Talley NJ, Boyle PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol (2002) 97(9):2269–9. doi:10.1111/j.1573-2241.2002.05783.x
4. Levy RL, Olden KW, Naliboff BD, Bradley LA, Franciscioni C, Drossman DA, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology (2006) 130(5):1447–58. doi:10.1053/j.gastro.2005.11.057
5. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology (2004) 126(6):1504–17. doi:10.1053/j.gastro.2004.01.063
6. Duriscova D, Burisch J, Jess T, Gower-Rousseau C, Lakatos PL; On Behalf of Ecco-EptCom. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohns Colitis (2014), doi:10.1016/j.crohns.2014.05.006
7. Guarner F, Khan AG, Garisch J, Eliaikim R, Gangl A, Thomson A, et al. World gastroenterology organisation global guidelines: prebiotics and probiotics October 2011. J Clin Gastroenterol (2012) 46(6):468–81. doi:10.1097/MCG.0b013e3182549092
8. Roberfroid M. Dietary fiber, inulin, and oligofructose: a review comparing their physiological effects. Crit Rev Food Sci Nutr (1993) 33(2):103–48. doi:10.1080/10408399309527616
9. Novak M, Vetvicka V. Beta-glucans, history, and the present: immunomodu- latory aspects and mechanisms of action. J Immunotoxicol (2008) 5(1):47–57. doi:10.1177/1547691008019045
10. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic, Nat Rev Gastroenterol Hepatol (2014) 11(8):506–14. doi:10.1038/nrgastro.2014.66
11. Simrén M, Barbera G, Flint HI, Spiegel BM, Spiller RC, Vanner S, et al. Intesti- nal microbiota in functional bowel disorders: a Rome foundation report. Gut (2013) 62(1):159–76. doi:10.1136/gutjnl-2012-302167
12. De Palma G, Collins SM, Berck P. The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes (2014) 5:3. doi:10.4161/gmic.29147
13. Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroen- terology (2006) 130(5):1527–37. doi:10.1053/j.gastro.2005.08.063
14. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology (1991) 100(4):988–1005.
15. Baussnerman M, Michail S. The use of Lactobacillus GG in irritable bowel syn- drome in children: a double-blind randomized control trial. J Pediatr (2005) 147(2):197–201. doi:10.1016/j.jpeds.2005.05.015
16. Spiller R, Aziz Q, Creed F, Emamuel A, Houghton L, Hungin P, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut (2007) 56(12):1770–88. doi:10.1136/gut.2007.119446
17. Krus W, Chrubasik S, Boehm S, Stange C, Schulze J, et al. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis (2012) 27(4):467–74. doi:10.1007/s00384-011-1363-9
18. Quigley EM, Faurie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil (2007) 19(3):166–72. doi:10.1111/j.1365-3162.2006.08879.x
19. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Meza J, Spiller RC. Functional bowel disorders. Gastroenterology (2006) 130(5):1480–91. doi:10.1053/j.gastro.2005.11.061
20. Saps M, Pensiabe C, Di Martino L, Staiano A, Wechsler J, Zheng X, et al. Post-infectious functional gastrointestinal disorders in children. J Pediatr (2008) 152(6):812–6. doi:10.1016/j.jpeds.2007.11.042
21. Kassinen A, Krogius-Kurikkla L, Makivuokko H, Rintila T, Paulin L, Korander J, et al. The fecal microbiota of irritable bowel syndrome patients differs sig- nificantly from that of healthy subjects. Gastroenterology (2007) 133(1):24–33. doi:10.1053/j.gastro.2007.04.005
22. Carroll BM, Rinzel-Kulka T, Sipple JP, Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil (2012) 24(6):521–30, e248. doi:10.1111/j.1365-3162.2012.01891.x
23. Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology (2011) 141(5):1782–91. doi:10.1053/j.gastro.2011. 06.072
24. Johnson AC, Greenwood-Van Meerveld B, McRorie J. Effects of *Bifidobacterium infantis* 35624 on post-inflammatory visceral hypersensitivity in the rat. *Dig Dis Sci* (2011) 56(1):3379–86. doi:10.1007/s10620-011-1730-y
25. Collins SM, Saturet M, Bercik P. The interplay between the intestinal microbiota and the brain. *Nat Rev Microbiol* (2012) 10(11):735–42. doi:10.1038/nrmicro2876
26. Camilleri M. Management of the irritable bowel syndrome. *Gastroenterology* (2001) 120(3):582–68. doi:10.1053/j.gastro.2001.21908
27. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. *World J Gastroenterol* (2008) 14(17):2650–61. doi:10.3748/wjg.v14.i17.2650
28. Guandalini S, Magazzù G, Chiaro A, La Balestra V, Di Nardo G, Gopalan S, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multi-center, randomized, placebo-controlled, double-blind, crossover study. *J Pediatr Gastroenterol Nutr* (2010) 51(1):24–30. doi:10.1097/MJP.0b013e3181ca4d85
29. Korterin H, Ockeleon L, Benninga MA, Tabbers MM, Hilbink M, Deckers-Kocken JM. Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis. *Acta Paediatr* (2014) 103(4):635–72. doi:10.1111/apa.12513
30. Gawronska A, Dzehciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of *Lactobacillus GG* for abdominal pain disorders in children. *Aliment Pharmacol Ther* (2007) 25(2):177–84. doi:10.1111/j.1365-2036.2006.03175.x
31. Romano C, Ferrau’ V, Cavatao E, Iacono G, Spina M, Lionietsi E, et al. *Lactobacillus reuteri* in children with functional abdominal pain (FAP). *J Pediatr Child Health* (2010). doi:10.1111/j.1442-200X.2010.04179.x
32. Francavilla R, Lionietsi E, Castellaneta S, Ciruzzi F, Indrio F, Mascale A, et al. Randomised clinical trial: *Lactobacillus reuteri* DSM 17938 vs placebo in children with acute diarrhoea – a double-blind study. *Aliment Pharmacol Ther* (2012) 36(6):689–96. doi:10.1111/j.1365-2036.2012.05180.x
33. Banaszkewicz A, Szajewska H. Ineffectiveness of *Lactobacillus GG* as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. *J Pediatr* (2005) 146(3):364–9. doi:10.1016/j.jpeds.2004.10.022
34. Bu LN, Chang MH, Ni YH, Chen HL, Cheng CC. *Lactobacillus casei rhamnosus* DN-173 010 on constipation in childhood: a multi-centre, randomised controlled trial. *J Biotechnol* (2011) 157(4):391–6. doi:10.1016/j.jbiotec.2011.06.017
35. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of active mild-to-moderate ulcerative colitis. *Med Sci Monit* (2004) 10(1):126–31.
36. Bifidobacterium lactis*. A new approach in therapy of *Escherichia coli* diarrhea in children. *Am J Gastroenterol* (2002) 97(6):1570–5.
37. Sood A, Midha V, Mackaria HK, Ahuja V, Goswami P, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. *Clin Gastroenterol Hepatol* (2009) 7(11):1202–9, 1209.e1. doi:10.1016/j.cgh.2009.07.016
38. Reister M, Hoffmeier K, Kreuznagl N, Rotter B, Liang C, Rund S, et al. Complete genome sequence of the Gram-negative probiotic *Escherichia coli* strain Nissle 1917. *J Biotechnol* (2014). doi:10.1016/j.jbiotec.2014.07.442
39. Petersen AM, Misrepasi H, Halkjar SI, Mortensen EM, Nordgaard-Lassen I, Kroglert KA. *Ciproflaxacin and probiotic Escherichia coli* Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. *J Crohns Colitis* (2014). doi:10.1016/j.crohns.2014.06.001
40. Malchow HA. *Crohn's disease and Escherichia coli*: A new approach in therapy to maintain remission of colonic Crohn's disease. *J Clin Gastroenterol* (1997) 25(4):638–8. doi:10.1097/00004836-199712000-00021
41. Prantera C, Seribano ML, Falasco G, Andreoli A, Lui C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised 12-week, double-blind, placebo-controlled trial with *Lactobacillus GG*. *Gut* (2002) 51(3):403–9. doi:10.1136/gut.51.3.405
42. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. *Lactobacillus GG* in inducing and maintaining remission of Crohn's disease. *BMC Gastroenterol* (2004) 4:5. doi:10.1186/1471-230X-4-5
43. Marteau P, Lémann M, Sekaï P, Laharie D, Colombel JF, Bouchik Y, et al. Ineffectiveness of *Lactobacillus johnsonii* LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomized, double-blind, placebo controlled GETAID trial. *Gut* (2006) 55(6):842–7. doi:10.1136/gut.2005.076604
44. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine P, et al. Multicenter randomised-controlled clinical trial of probiotics (*Lactobacillus johnsonii*, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. *Inflamm Bowel Dis* (2007) 13(2):135–42. doi:10.1002/ibd.20063
45. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. *Inflamm Bowel Dis* (2014) 20(1):21–35. doi:10.1097/MIB.0b013e318276052e
46. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine P, et al. Multicenter randomised-controlled clinical trial of probiotics (*Lactobacillus johnsonii*, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. *Inflamm Bowel Dis* (2007) 13(2):135–42. doi:10.1002/ibd.20063.
61. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. *Aliment Pharmacol Ther* (2009) 29(5):508–18. doi:10.1111/j.1365-2036.2008.03911.x

62. Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. *J Gastroenterol Hepatol* (2010) 25(8):1366–73. doi:10.1111/j.1440-1746.2010.06370.x

63. Staudacher HM, Irving PM, Lomer MC, Whelan K. Mechanisms and efficacy of dietary FODMAP restriction in IBS. *Nat Rev Gastroenterol Hepatol* (2014) 11(4):256–66. doi:10.1038/nrgastro.2013.259

64. Major G, Teale A, Pritchard S, Marciani L, Whelan K, Gowland P, et al. OC-070 dietary supplementation with fodmaps increases fasting colonic volume and breath hydrogen in healthy volunteers: a mechanistic study using Mri. *Gut* (2014) 63(Suppl 1):A35. doi:10.1136/gutjnl-2014-307263.70

65. Araki Y, Kanauchi O, Sugihara H, Fujiyama Y, Hattori T. Germinated barley foodstuff suppresses dextran sulfate experimental colitis in rats: the role of mast cells. *Int J Mol Med* (2007) 19(2):257–62.

66. Bovee-Oudenhoven IM, ten Bruggencate SJ, Lettink-Wissink ML, van der Meer R. Dietary fructo-oligosaccharides and lactulose inhibit intestinal colonisation but stimulate translocation of salmonella in rats. *Gut* (2003) 52(11):1572–8. doi:10.1136/gut.52.11.1572

67. Fukuda M, Kanauchi O, Araki Y, Andoh A, Mitsuyama K, Takagi K, et al. Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. *Int J Mol Med* (2002) 9(1):65–70.

68. Hoentjen F, Welling GW, Harmens HJ, Zhang X, Snart J, Tannock GW, et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. *Inflamm Bowel Dis* (2005) 11(11):977–85. doi:10.1097/01.MIB.0000183421.02316.d5

69. Lindsay JO, Whelan K, Stagg AL, Gohin P, Al-Hassi HO, Rayment N, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. *Gut* (2006) 55(3):348–55. doi:10.1136/gut.2005.074971

70. Benjamin JL, Hedin CR, Koutroumpas A, Ng SC, McCarthy NE, Hart AL, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. *Gut* (2011) 60(7):923–9. doi:10.1136/gut.2010.232025

71. Bamba T, Kanauchi O, Andoh A, Fujiyama Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. *J Gastroenterol Hepatol* (2002) 17(8):818–24. doi:10.1046/j.1440-1746.2002.02709.x

72. Kanauchi O, Suga T, Tochihara M, Hibi T, Naganuma M, Homma T, et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. *J Gastroenterol* (2002) 37(Suppl 14):67–72. doi:10.1007/BF03326417

73. Casellas F, Borruei N, Torrejón A, Varela E, Antolin M, Guarner F, et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. *Aliment Pharmacol Ther* (2007) 25(9):1061–7. doi:10.1111/j.1365-2036.2007.03288.x

Conflict of Interest Statement: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 18 July 2014; accepted: 07 August 2014; published online: 28 August 2014. Citation: Guandalini S (2014) Are probiotics or prebiotics useful in pediatric irritable bowel syndrome or inflammatory bowel disease? *Front. Med.* 1:23. doi:10.3389/fmed.2014.00023

This article was submitted to Gastroenterology, a section of the journal *Frontiers in Medicine*. Copyright © 2014 Guandalini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.